Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gene Logic/Oncormed

This article was originally published in The Gray Sheet

Executive Summary

Firms ink definitive agreement under which Gene Logic acquires Oncormed in a stock deal valued at up to $38 mil. Oncormed, which uses proprietary genomics technologies and software to characterize genes to establish clinical relevance and to profile patients for pharmacogenomic and therapeutic purposes, had handed over its BRCA1/BRCA2 breast and ovarian genetic testing business to Myriad Genetics under a May patent infringement settlement ("The Gray Sheet" May 25, In Brief). Gene Logic's buy provides "the critical mass and range of technologies necessary to support key aspects of the drug discovery and development process," Gene Logic says



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts